Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445088 proof-of-concept study in CIDP
NL-OMON59846Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (7 arms), sponsored by Sanofi. Started Dec 2021; status: completed.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON59846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59846.